What is one game-changing idea that didn’t come to pass in 2017 that you think will this year?
The power of AI and predictive analytics, fueled by real-world healthcare data, has yet to be fully realized by biopharmaceutical companies and is poised to revolutionize their business strategies.
Advanced analytics can find HCPs who are currently managing yet-to-be-diagnosed patients with hard-to-diagnose diseases and identify impactful clinical networks that can be leveraged to change clinician behavior.
Robert Gabruk, managing director
Address: 750 Third Avenue, Suite 1003, New York, NY 10017
Year Founded: 2006
Holding Company: None
Sample Clients: Small to large biopharmaceutical companies
New Business Contact: Robert Gabruk, managing director, 646-416-5653, [email protected]
81qd, an advanced healthcare data analytics company, provides life sciences organizations with customized, cost-effective solutions designed to maximize their brands’ commercial potential through all stages of product development and commercialization.
Our multidisciplinary team of data scientists, medical strategists, and marketing professionals have decades of experience in healthcare analytics. 81qd is differentiated by our ability to provide end-to-end solutions, from strategic planning to tactical execution. We are at the forefront of the latest advances in data science, which power our proprietary solutions to solve our clients’ business challenges.
SERVICES AND OFFERINGS
Actionable, AI-driven analytics fueled by real-world data.
Plexus, our machine learning-based solution, identifies the true clinical influencers — those individuals who impact the care of patients far beyond their own practice by influencing the behavior of other clinicians. This provides our clients the competitive advantage of being able to leverage the most influential clinicians in a specific disease state to drive the diffusion of innovation through influence-based marketing.
Orion, our patient-finding solution, utilizes predictive analytics to identify specific clinicians currently managing yet-to-be-diagnosed patients with diseases that are difficult to diagnose. This proprietary solution leverages machine learning and computational statistics to analyze disparate sources of data — including healthcare encounter data, laboratory data, and electronic health records — to reliably predict which patients have the highest probability of having a particular difficult-to-diagnose disease.
Acuity, our global stakeholder management platform, employs industry-leading methodologies for data mining, cleansing, and disambiguation to identify and profile clinicians.
Our analyses are derived from disparate sources of data that are carefully curated to meet the specific needs of individual clients. As our clients continue to build a wealth of data on thought leaders, we provide them with customized dashboards to identify, measure, and track thought leader engagements.
From the March 02, 2018 Issue of MM+M - Medical Marketing and Media